eGenesis Announces $38 Million Series A Financing, Led by Biomatics Capital and ARCH Venture Partners, to Solve Shortage of Organs for Donation

CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--eGenesis, a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million ... Regenerative Medicine, Venture Capital eGenesis, xenotransplantation, organ transplant
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news